Giuseppe Orefice
e-mail: orefice AT unina.it
website: www.unina.it
affiliation: Università di Napoli Federico II
research area(s): Neuroscience
Courses:
- Neurosciences
- Molecular Pathology and Pathophysiology
1967- 1974; Medical Student at the 2nd School of Medicine of Naples, Italy
1974: Degree in Medicine
1977: Degree cum laude in Neurology at the Department of Neurological Sciences,
University "Federico II", Naples
1980: Degree cum laude in Endocrinology at the University "Federico ll", Naples
1980-2008; Researcher at the Department of Neurological Sciences, University
"Federico II", Naples
2005: Director of the Rehabilitation Unit at the Department of Neurological
Sciences, University "Federico II", Naples
2008: Associate Professor at the Department of Neurological Sciences, University
"Federico II", Naples
Active participation in clinical study about multiple sclerosis.
Good acknowledge about the Good Clinical Practice.
Professor Orefice has published 135 papers, 50 of which published on peer reviewed
scientific journals.
1974: Degree in Medicine
1977: Degree cum laude in Neurology at the Department of Neurological Sciences,
University "Federico II", Naples
1980: Degree cum laude in Endocrinology at the University "Federico ll", Naples
1980-2008; Researcher at the Department of Neurological Sciences, University
"Federico II", Naples
2005: Director of the Rehabilitation Unit at the Department of Neurological
Sciences, University "Federico II", Naples
2008: Associate Professor at the Department of Neurological Sciences, University
"Federico II", Naples
Active participation in clinical study about multiple sclerosis.
Good acknowledge about the Good Clinical Practice.
Professor Orefice has published 135 papers, 50 of which published on peer reviewed
scientific journals.
Trials ongoing:
- PEA add-on treatment in Relapsing-Remitting multiple sclerosis: a double-blind randomized case control study
- PEA add-on treatment in Primary-Progressive multiple sclerosis: a double-blind randomized case control study
- The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)
- Rehabilitation in Parkinson disease complicated with freezing of gait
- The Italian Validation of the Unified Dyskinesia Rating Scale (ALTHEA study)
- The role of neurosteroids in Multiple sclerosis
- Defence: Cortical lesion in Multiple sclerosis
All this project are available for students for the academic year. All students have the opportunity to take part to all this project with a supervisor.
- PEA add-on treatment in Relapsing-Remitting multiple sclerosis: a double-blind randomized case control study
- PEA add-on treatment in Primary-Progressive multiple sclerosis: a double-blind randomized case control study
- The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)
- Rehabilitation in Parkinson disease complicated with freezing of gait
- The Italian Validation of the Unified Dyskinesia Rating Scale (ALTHEA study)
- The role of neurosteroids in Multiple sclerosis
- Defence: Cortical lesion in Multiple sclerosis
All this project are available for students for the academic year. All students have the opportunity to take part to all this project with a supervisor.
- Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 2013 Aug 30;8(8)
- Picillo M, Amboni M, Erro R, Longo K, Vitale C, Moccia M, Pierro A, Santangelo G, De Rosa A, De Michele G, Santoro L, Orefice G, Barone P, Pellecchia MT. Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. J Neurol. 2013 Nov;260(11):2849-55. doi: 10.1007/s00415-013-7085-x.
- Picillo M, Pellecchia MT, Erro R, Amboni M, Vitale C, Iavarone A, Moccia M, Allocca R, Orefice G, Barone P. The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. Neurol Sci.Aug 22.
- Erro R, Vitale C, Amboni M, Picillo M, Moccia M, Longo K, Santangelo G, De Rosa A, Allocca R, Giordano F, Orefice G, De Michele G, Santoro L, Pellecchia MT, Barone P. The heterogeneity of early Parkinson's disease: a cluster analysis onnewly diagnosed untreated patients. PLoS One. 2013 Aug 1;8(8)
- Lanzillo R, Bonavita S, Quarantelli M, Vacca G, Lus G, Amato L, Carotenuto A, Tedeschi G, Orefice G, Brescia Morra V. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci. 2013 Apr;34(4):521-8. doi: 10.1007/s10072-012-1088-8.
- Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M,Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol. 2012 Mar 5;12:7.
- Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand. 2012 Nov;126(5):306-14
- Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Gasperi M, Prinster A, Vacca G, Pivonello C, Orefice G, Colao A, Morra VB. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Eur J Neurol. 2011 Dec;18(12):1402-6.
- Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010 Apr;16(4):450-4.
- Prinster A, Quarantelli M, Lanzillo R, Orefice G, Vacca G, Carotenuto B, Alfano B, Brunetti A, Morra VB, Salvatore M. A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis. Mult Scler. 2010 Jan;16(1):45-54. doi: 10.1177/1352458509351896. Epub 2009 Dec 22.
- Picillo M, Amboni M, Erro R, Longo K, Vitale C, Moccia M, Pierro A, Santangelo G, De Rosa A, De Michele G, Santoro L, Orefice G, Barone P, Pellecchia MT. Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. J Neurol. 2013 Nov;260(11):2849-55. doi: 10.1007/s00415-013-7085-x.
- Picillo M, Pellecchia MT, Erro R, Amboni M, Vitale C, Iavarone A, Moccia M, Allocca R, Orefice G, Barone P. The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. Neurol Sci.Aug 22.
- Erro R, Vitale C, Amboni M, Picillo M, Moccia M, Longo K, Santangelo G, De Rosa A, Allocca R, Giordano F, Orefice G, De Michele G, Santoro L, Pellecchia MT, Barone P. The heterogeneity of early Parkinson's disease: a cluster analysis onnewly diagnosed untreated patients. PLoS One. 2013 Aug 1;8(8)
- Lanzillo R, Bonavita S, Quarantelli M, Vacca G, Lus G, Amato L, Carotenuto A, Tedeschi G, Orefice G, Brescia Morra V. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci. 2013 Apr;34(4):521-8. doi: 10.1007/s10072-012-1088-8.
- Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M,Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol. 2012 Mar 5;12:7.
- Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand. 2012 Nov;126(5):306-14
- Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Gasperi M, Prinster A, Vacca G, Pivonello C, Orefice G, Colao A, Morra VB. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Eur J Neurol. 2011 Dec;18(12):1402-6.
- Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010 Apr;16(4):450-4.
- Prinster A, Quarantelli M, Lanzillo R, Orefice G, Vacca G, Carotenuto B, Alfano B, Brunetti A, Morra VB, Salvatore M. A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis. Mult Scler. 2010 Jan;16(1):45-54. doi: 10.1177/1352458509351896. Epub 2009 Dec 22.
Project Title:
Project Title:
See Reasearch activity
See Reasearch activity
Project Title:
See Reasearch activity
See Reasearch activity